|1.||Ahmad, Mohammad: 2 articles (11/2014 - 01/2014)|
|2.||Dehpour, Ahmad Reza: 2 articles (06/2004 - 04/2002)|
|3.||Homayoun, Houman: 2 articles (06/2004 - 04/2002)|
|4.||Wadaan, Mohammad A M: 1 article (11/2014)|
|5.||Aboshaiqah, Ahmad E: 1 article (01/2014)|
|6.||Abu-Taweel, Gasem M: 1 article (01/2014)|
|7.||Ajarem, Jamaan S: 1 article (01/2014)|
|8.||Mestriner, Fabíola Leslie: 1 article (01/2013)|
|9.||Cárnio, Evelin Capellari: 1 article (01/2013)|
|10.||Queiróz Cunha, Fernando: 1 article (01/2013)|
05/01/2003 - "Mean pain scores fell from a baseline of 8.12-7.89 during the placebo phase (N.S.) and to 6.82 during the proglumide phase (P < 0.05). "
03/01/1986 - "Pain modulation appears to be a major effect of CCK and proglumide, its antagonist. "
03/01/1986 - "CCK's inhibitory effect and proglumide's potentiating effect on opiate analgesia may have clinical application; proglumide's inhibitory effect on opiate tolerance may help in management of chronic pain. "
05/01/1998 - "Nonetheless, this study suggests that proglumide may have use as an opioid adjunct in patients with cancer pain."
11/15/2006 - "Importantly, both diazepam and proglumide did not show analgesic properties on basal pain, because they acted only on the nocebo-induced pain increase. "
|2.||Duodenal Ulcer (Curling's Ulcer)
04/10/1981 - "[Duodenal ulcer - multicenter double-blind study with proglumide]."
03/02/1979 - "There was no significant effect of proglumide on duodenal ulcers (17 in the proglumide and 18 in the placebo groups). "
03/21/1969 - "[Evaluation of the therapeutic activity of CR 242 or Xylamide in the treatment of gastric and duodenal ulcers and of gastroduodenitis]."
01/01/1989 - "20 patients with peptic gastric ulcer and 30 patients with peptic duodenal ulcer were treated with Milid (Proglumid). "
08/01/1979 - "Eleven male and five female gastric ulcer outpatients as well as twenty eight male and seven female duodenal ulcer outpatients received Proglumide (1200 mg/day) or magnesiumtrisilicate (1320 mg/day) in a prospective double blind study. "
01/01/1989 - "The results of this study demonstrate that CCK has an important role in the development of acute pancreatitis and that proglumide might have prophylactic and therapeutic effects in acute pancreatitis."
01/01/1997 - "Therefore, we have also examined the effect of proglumide on the somatostatinergic system in controls and rats with acute pancreatitis. "
03/01/1988 - "The results do not support proglumide as the sole treatment in acute pancreatitis."
03/01/1988 - "Proglumide treatment in bile-induced acute experimental pancreatitis."
01/01/1997 - "Proglumide, a CCK receptor antagonist reduces the severity of acute pancreatitis in the rat. "
|4.||Brain Ischemia (Cerebral Ischemia)
09/01/1987 - "Studies were conducted to clarify the possible role of CCK in cerebral ischemia and to evaluate the effects of proglumide, a competitive and reversible CCK antagonist, as a potential therapeutic or prophylactic tool in the treatment of cerebral ischemia. "
09/01/1987 - "The influence of proglumide, a putative CCK antagonist, on cerebral ischemia in gerbil."
09/01/1987 - "These results suggest that CCK may be involved in the pathological processes of cerebral ischemia and proglumide or related compounds prove to be effective in the pharmacological prophylaxis of ischemic brain damage."
06/01/2004 - "Moreover, proglumide exerted a similar inhibition of the anticonvulsant effect and potentiation of the antinociceptive effect of acute morphine at 1 mg/kg. In contrast, brief and continuous footshock stress (3 min) that induced a nonopioid type of antinociception did not increase the seizure threshold. "
06/01/2004 - "While CCK receptor antagonist proglumide (10, 20, or 40 mg/kg) had no effect on seizure or nociception threshold by itself, it inhibited the anticonvulsant effects of both these types of stress while potentiating their antinociceptive effects. "
01/01/2014 - "Quinacrine (Qcn), proglumide (Pgm), and pentoxifylline (Ptx) administered to animals before inducing SE, were significantly effective in ameliorating the seizure activities, cognitive dysfunctions, and cerebral OS. "
12/01/1985 - "Proglumide, an antagonist of cholecystokinin receptors, in low dose (5 mg/kg) potentiated the effects of caerulein (100 micrograms/kg), whereas the administration of proglumide in high dose (25 mg/kg) reduced the action of caerulein on 3H-flunitrazepam binding and picrotoxin seizures. "
01/01/2014 - "The effects of quinacrine, proglumide, and pentoxifylline on seizure activity, cognitive deficit, and oxidative stress in rat lithium-pilocarpine model of status epilepticus."
|1.||Cholecystokinin Receptors (Cholecystokinin Receptor)
|3.||Morphine (MS Contin)
|10.||Cholecystokinin B Receptor
|3.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)